In December, German drug manufacturer and biotech company BioNTech initiated a study to evaluate its experimental malaria vaccine in humans, according to Reuters. The trial's first phase was expected to include 60 U.S. volunteers with no history of malaria to assess the vaccine candidate at three-dose levels.
The first vaccine candidate from BioNTech's malaria project is known as BNT165b1 and was said to also establish vaccine production in Africa. hmmmm these fkrs are all everywhere
In December, German drug manufacturer and biotech company BioNTech initiated a study to evaluate its experimental malaria vaccine in humans, according to Reuters. The trial's first phase was expected to include 60 U.S. volunteers with no history of malaria to assess the vaccine candidate at three-dose levels.
The first vaccine candidate from BioNTech's malaria project is known as BNT165b1 and was said to also establish vaccine production in Africa. hmmmm these fkrs are all everywhere